Retrovirally expressed 4-1BBL dramatically increases proliferation and in vivo persistence of adoptively transferred CD19-targeted T cells, promoting complete tumor elimination.

被引：0

作者：

Condomines, Maud ^{[1
]}

Plotkin, Jason ^{[1
]}

Markley, John ^{[1
]}

Gunset, Gertrude ^{[1
]}

Sadelain, Michel ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, New York, NY 10021 USA

来源：

JOURNAL OF IMMUNOLOGY | 2010年 / 184卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

131.16

引用

页数：1

共 9 条

[1] Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Brentjens, Renier J.
Riviere, Isabelle
Park, Jae H.
Davila, Marco L.
Wang, Xiuyan
Stefanski, Jolanta
Taylor, Clare
Yeh, Raymond
Bartido, Shirley
Borquez-Ojeda, Oriana
Olszewska, Malgorzata
Bernal, Yvette
Pegram, Hollie
Przybylowski, Mark
Hollyman, Daniel
Usachenko, Yelena
Pirraglia, Domenick
Hosey, James
Santos, Elmer
Halton, Elizabeth
Maslak, Peter
Scheinberg, David
Jurcic, Joseph
Heaney, Mark
Heller, Glenn
Frattini, Mark
Sadelain, Michel
BLOOD, 2011, 118 (18) : 4817 - 4828
[2] Adoptively transferred tumor-specific T cells expanded ex vivo using HSV amplicons encoding 4-1BBL show increased anti-tumor activity in vivo
Yi, Kyung H.
Nechushtan, Hovav
Zhang, Yu
Bowers, William J.
Federoff, Howard J.
Pham, Dien G.
Podack, Eckhard R.
Rosenblatt, Joseph D.
CANCER RESEARCH, 2006, 66 (08)
[3] Adoptively transferred tumor-specific T cells expanded ex vivo using HSV amplicons encoding 4-1BBL persist in the host and demonstrate anti-tumor activity in vivo
Yi, Kyung Hee
Nechushtan, Hovav
Zhang, Yu
Bowers, William J.
Tolba, Khaled A.
Podack, Eckhard R.
Federoff, Howard J.
Rosenblatt, Joseph D.
JOURNAL OF IMMUNOLOGY, 2007, 178
[4] Adoptively transferred tumor-specific T cells stimulated Ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity In vivo
Yi, Kyung H.
Nechushtan, Hovav
Bowers, William J.
Walker, Gail R.
Zhan, Yu
Pham, Dien G.
Podack, Eckhard R.
Federoff, Howard J.
Tolba, Khaled A.
Rosenblatt, Joseph D.
CANCER RESEARCH, 2007, 67 (20) : 10027 - 10037
[5] Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells
Brentjens, Renier J.
Hollyman, Daniel
Park, Jae
Santos, Elmer
Yeh, Raymond
Stefanski, Jolanta
Taylor, Clare
Weiss, Mark A.
Filippa, Daniel
Riviere, Isabelle
Sadelain, Michel W.
BLOOD, 2009, 114 (22) : 1335 - 1335
[6] CD28-costimulation provided through a CD19-specific chimeric immunoreceptor enhances in vivo persistence and anti-tumor efficacy of adoptively transferred T cells.
Kowolik, CM
Gonzalez, S
Olivares, S
Jensen, M
Cooper, LN
BLOOD, 2005, 106 (11) : 372A - 372A
[7] A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia.
Park, Jae Hong
Riviere, Isabelle
Wang, Xiuyan
Senechal, Brigitte
Bernal, Yvette
Halton, Elizabeth
Diamonte, Claudia
Wang, Yongzeng
Brentjens, Renier J.
Sadelain, Michel
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation
Park, Jae H.
Palomba, Maria Lia
Batlevi, Connie Lee
Riviere, Isabelle
Wang, Xiuyan
Senechal, Brigitte
Furman, Richard R.
Bernal, Yvette
Hall, Malloury
Pineda, John
Diamonte, Claudia
Halton, Elizabeth
Brentjens, Renier J.
Sadelain, Michel
BLOOD, 2018, 132
[9] Mouse CD19-targeted CAR T cells with an optimized 4-1BB domain enhance protection against CD19+leukemia and retain proliferation potential after long-term rest in vivo.
Li, Gongbo
Beatty, Nolan
Vishwasrao, Paresh
Yu, Bin
Park, Paul
Zhang, Yongliang
Davila, Marco L.
JOURNAL OF IMMUNOLOGY, 2017, 198 (01):

← 1 →